

Kentucky Medicaid COVID 19 Antibody Infusion Therapy Revised 2/2/2023



Code	Short Descriptor	Long Descriptor	Payment	Notes
M0220	TIXAGEV AND CILGAV INJ	INJECTION, TIXAGEVIMAB AND CILGAVIMAB, FOR THE PRE-EXPOSURE PROPHYLAXIS ONLY, FOR CERTAIN ADULTS AND PEDIATRIC INDIVIDUALS (12 YEARS OF AGE AND OLDER WEIGHING AT LEAST 40KG) WITH NO KNOWN	\$150.50	eff 12/8/21
M0221	TIXAGEV AND CILGAV INJ HM	INJECTION, TIXAGEVIMAB AND CILGAVIMAB, FOR THE PRE-EXPOSURE PROPHYLAXIS ONLY, FOR CERTAIN ADULTS AND PEDIATRIC INDIVIDUALS (12 YEARS OF AGE AND OLDER WEIGHING AT LEAST 40KG) WITH NO KNOWN	\$250.50	eff 12/8/21
M0222	BEBTELOVIMAB INJECTION	INTRAVENOUS INJECTION, BEBTELOVIMAB, INCLUDES INJECTION AND POST ADMINISTRATION MONITORING	\$350.50	eff 2/11/22 through 11/30/2022
M0223	BEBTELOVIMAB INJECTION HOME	INTRAVENOUS INJECTION, BEBTELOVIMAB, INCLUDES INJECTION AND POST ADMINISTRATION MONITORING IN THE HOME OR RESIDENCE; THIS INCLUDES A BENEFICIARY'S HOME THAT HAS BEEN MADE PROVIDER-BASED TO THE HOSPITAL DURING THE COVID-19 PUBLIC HEALTH EMERGENCY	\$550.50	eff 2/11/22 through 11/30/2022
M0240	Casirivi and imdevi repeat	Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring, subsequent repeat doses	\$450.00	eff 10/1/21
M0241	Casirivi and imdevi repeat hm	Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring in the home or residence, this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency, subsequent repeat doses	\$750.00	eff 10/1/21
M0243	Casirivi and imdevi inj	Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring	\$450.00	eff 11/21/20, new Rate effective 10/1/21
M0244	Casirivi and imdevi inj hm	Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency	\$750.00	eff 5/6/2, new rate effective 10/1/21
M0245	Bamlan and etesev infusion	intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring	\$450.00	eff 2/9/21
M0246	Bamlan and etesev infus home	Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency	\$750.00	eff 5/6/2, new rate effective 10/1/21
M0247	Sotrovimab infusion	Intravenous infusion, sotrovimab, includes infusion and post administration monitoring	\$450.00	eff 10/1/21
M0248	Sotrovimab inf, home admin	Intravenous infusion, sotrovimab, includes infusion and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency	\$750.00	eff 10/1/21

M0249	Adm Tocilizu COVID-19 1st	Intravenous infusion, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) only, includes infusion and post administration monitoring, first dose	\$450.00	eff 10/1/21
M0250	Adm Tocilizu COVID-19 2nd	Intravenous infusion, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) only, includes infusion and post administration monitoring, second dose	\$450.00	eff 10/1/21
Q0220	TIXAGEV AND CILGAV, 300MG	INJECTION, TIXAGEVIMAB AND CILGAVIMAB, FOR THE PRE-EXPOSURE PROPHYLAXIS ONLY, FOR CERTAIN ADULTS AND PEDIATRIC INDIVIDUALS (12 YEARS OF AGE AND OLDER WEIGHING AT LEAST 40KG) WITH NO KNOWN	\$0.00	eff 12/8/21
Q0221	TIXAGEV AND CILGAV, 600MG	INJECTION, TIXAGEVIMAB AND CILGAVIMAB, FOR THE PRE-EXPOSURE PROPHYLAXIS ONLY, FOR CERTAIN ADULTS AND PEDIATRIC INDIVIDUALS (12 YEARS OF AGE AND OLDER WEIGHING AT LEAST 40KG) WITH NO KNOWN	\$0.00	eff 2/24/22
Q0222	BEBTELOVIMAB 175 MG	INJECTION, BEBTELOVIMAB, 175 MG	\$2,394.00	eff 2/11/22 through 11/30/2022